Press Release

Our enduring purpose: To fundamentally improve the lives of patients with serious diseases in ways never before possible

Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences

June 9, 2019 at 3:00 PM EDT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 9, 2019-- Five Prime Therapeutics, Inc.(NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer, is scheduled to present at the following two investor conferences:

  • The Raymond James Life Sciences and MedTech Conference, on Wednesday, June 19th at 1:15pm ET / 10:15am PT
  • The 2019 Bank of Montreal Prescriptions for Success Healthcare Conference on Tuesday, June 25th at 3:00pm ET / 12:00pm PT

The presentations will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at: Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative protein therapeutics to improve the lives of patients with serious diseases. Five Prime’s product candidates have innovative mechanisms of action and address patient populations in need of better therapies. The company focuses on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit or follow us on LinkedIn, Twitter and Facebook.

Source: Five Prime Therapeutics, Inc.

Source: Five Prime Therapeutics, Inc.

Media and Investor Contact
Martin Forrest
VP, Investor Relations & Corporate Communications
Five Prime Therapeutics, Inc.